‘The courses I took as part of the MBiotech curriculum sparked my interest in clinical trial designs and risks, and inspired me to pursue this research opportunity. This project helped me further understand the complexities of clinical trials, as well as the many multifaceted factors physicians must consider when prioritising clinical trials for patients. This research topic complemented the learnings from the MBiotech program, and continuous support by the program and faculty (in particular Dr. Parker) allowed us to succeed in this research, thanks MBiotech!’
Application relevance: The study explored clinical trial design and biomarker choices that may improve clinical trial testing success rates of new medicines in leukæmia. The use of biomarkers dramatically improved success rates ranging from 3- to 7-fold depending upon the indication. These and other findings allow oncologists to prioritise oncology trials in which to enrol their patients.
